Literature DB >> 16755412

[Reliability and validity of the schedule for deficit syndrome in schizophrenia].

Serhat Citak1, E Timuçin Oral, A Tamer Aker, Mustafa Senocak.   

Abstract

OBJECTIVE: The Schedule for Deficit Syndrome (SDS) is an instrument for categorizing schizophrenic patients as those with and without deficit syndrome. This schedule has been translated and adapted into the Turkish language in order to study its reliability and validity.
METHOD: 30 male schizophrenic patients were included in the study. The patients had been ill for a long period of time and the course was continuous. The patients were assessed by two different raters using the SDS as a means of testing its reliability. A third rater assessed the same group of patients using the BPRS to test the validity of the SDS.
RESULTS: The raters using the SDS demonstrated good inter-rater reliability for the categorization of patients with and without deficit syndrome, as well as for rating global severity (kappa: 0.88-0.93) and individual negative symptoms (kappa: 0.51-0.61). The schedule was also found to have a high validity for both categorization and measuring individual negative symptoms. (U: 60.0, P: 0.03).
CONCLUSION: The results demonstrated that the Turkish version of the SDS would be a reliable and valid instrument that could be used in the study of schizophrenia.

Entities:  

Mesh:

Year:  2006        PMID: 16755412

Source DB:  PubMed          Journal:  Turk Psikiyatri Derg        ISSN: 1300-2163


  6 in total

1.  Are Negative Symptoms Dimensional or Categorical? Detection and Validation of Deficit Schizophrenia With Taxometric and Latent Variable Mixture Models.

Authors:  Anthony O Ahmed; Gregory P Strauss; Robert W Buchanan; Brian Kirkpatrick; William T Carpenter
Journal:  Schizophr Bull       Date:  2014-11-14       Impact factor: 9.306

2.  Inflammation and Oxidative Stress in Deficit Schizophrenia.

Authors:  Ferdi KÖŞger; Semra YİĞİtaslan; Altan EŞsİzoĞlu; Gülcan GÜleÇ; Reyhan DaĞ KarataŞ; Sinem Sevİl DeĞİrmencİ
Journal:  Noro Psikiyatr Ars       Date:  2020-09-21       Impact factor: 1.339

3.  Decreased serum levels of brain-derived neurotrophic factor in schizophrenic patients with deficit syndrome.

Authors:  Esra Soydaş Akyol; Yakup Albayrak; Murat Beyazyüz; Nurkan Aksoy; Murat Kuloglu; Kenji Hashimoto
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-30       Impact factor: 2.570

4.  Increased serum levels of apoptosis in deficit syndrome schizophrenia patients: a preliminary study.

Authors:  Murat Beyazyüz; Tarkan Küfeciler; Leyla Bulut; Cüneyt Ünsal; Yakup Albayrak; Esra Soydaş Akyol; Saliha Baykal; Murat Kuloglu; Kenji Hashimoto
Journal:  Neuropsychiatr Dis Treat       Date:  2016-05-23       Impact factor: 2.570

5.  EPA guidance on assessment of negative symptoms in schizophrenia.

Authors:  S Galderisi; A Mucci; S Dollfus; M Nordentoft; P Falkai; S Kaiser; G M Giordano; A Vandevelde; M Ø Nielsen; L B Glenthøj; M Sabé; P Pezzella; I Bitter; W Gaebel
Journal:  Eur Psychiatry       Date:  2021-02-18       Impact factor: 5.361

6.  Neurological soft signs might be endophenotype candidates for patients with deficit syndrome schizophrenia.

Authors:  Yakup Albayrak; Esra Soydaş Akyol; Murat Beyazyüz; Saliha Baykal; Murat Kuloglu
Journal:  Neuropsychiatr Dis Treat       Date:  2015-10-29       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.